Want to see HK:3309 full AI Analyst Report?
Top Page
C-MER Eye Care Holdings Limited
(3309)
Select Model
Select Model
Rating:64Neutral
Price Target:
HK$1.00
▼(-41.18% Downside)
Action:Reiterated
Date:04/21/26
The score is supported primarily by strong cash flow and a stable, moderately levered balance sheet, but is held back by weak technicals (broad downtrend and negative momentum) and only average valuation support (mid-range P/E and modest dividend yield).
Positive Factors
Cash generation
Consistent positive operating cash flow and strong free cash flow through 2022–2025 provide durable internal funding for capex, working capital and debt servicing. This lowers reliance on external financing, supports reinvestment in clinics, and bolsters resilience across medium-term cycles.
Negative Factors
Earnings volatility
Repeated swings into losses (notably 2022 and 2024) undermine earnings predictability and complicate medium-term planning. Volatility suggests sensitivity to patient volumes, pricing shifts or episodic costs, reducing confidence in sustained profit delivery absent clearer operational stability.
Read all positive and negative factors
Positive Factors
Negative Factors
Cash generation
Consistent positive operating cash flow and strong free cash flow through 2022–2025 provide durable internal funding for capex, working capital and debt servicing. This lowers reliance on external financing, supports reinvestment in clinics, and bolsters resilience across medium-term cycles.
Read all positive factors
C-MER Eye Care Holdings Limited (3309) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$1.18B
Dividend Yield2.08%
Average Volume (3M)495.46K
Price to Earnings (P/E)11.5
Beta (1Y)1.05
Revenue Growth1.75%
EPS GrowthN/A
CountryHK
Employees2,200
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)0.08
Shares Outstanding1,232,342,900
10 Day Avg. Volume419,185
30 Day Avg. Volume495,465
Financial Highlights & Ratios
PEG Ratio-0.12
Price to Book (P/B)1.17
Price to Sales (P/S)1.07
P/FCF Ratio9.26
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
C-MER Eye Care Holdings Limited Business Overview & Revenue Model
Company Description
C-MER Medical Holdings Limited specializes in offering both medical treatments and therapeutic services for a variety of eye conditions. Its business activities are segmented into two primary areas: the delivery of ophthalmological services and th...
How the Company Makes Money
C-MER primarily generates revenue by providing ophthalmic medical services to patients on a fee-for-service basis. Its key revenue streams typically include (1) outpatient services such as specialist consultations, eye examinations, and diagnostic...
C-MER Eye Care Holdings Limited Financial Statement Overview
Summary
Income Statement
73
Positive
Balance Sheet
78
Positive
Cash Flow
84
Very Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.95B | 1.91B | 1.92B | 1.73B | 1.11B |
| Gross Profit | 603.67M | 527.62M | 618.96M | 365.34M | 309.44M |
| EBITDA | 206.52M | 209.18M | 363.38M | 194.31M | 177.80M |
| Net Income | 100.37M | -135.16M | 62.00M | -21.88M | 21.86M |
Balance Sheet | |||||
| Total Assets | 2.73B | 2.72B | 2.75B | 2.90B | 1.96B |
| Cash, Cash Equivalents and Short-Term Investments | 465.96M | 467.25M | 557.42M | 698.51M | 442.36M |
| Total Debt | 426.78M | 437.79M | 362.99M | 452.49M | 471.69M |
| Total Liabilities | 796.01M | 830.24M | 755.35M | 903.45M | 618.63M |
| Stockholders Equity | 1.77B | 1.75B | 1.85B | 1.87B | 1.33B |
Cash Flow | |||||
| Free Cash Flow | 223.94M | 124.50M | 245.30M | 100.63M | 19.18M |
| Operating Cash Flow | 301.47M | 283.12M | 361.15M | 191.86M | 148.41M |
| Investing Cash Flow | -169.66M | -174.72M | -245.37M | -210.65M | -392.72M |
| Financing Cash Flow | -212.38M | -194.92M | -242.88M | 293.68M | 85.12M |
C-MER Eye Care Holdings Limited Technical Analysis
Negative
1.70
Price Trends
1.03
Negative
1.16
Negative
1.42
Negative
Market Momentum
-0.02
Negative
45.53
Neutral
66.67
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:3309, the sentiment is Negative. The current price of 1.7 is above the 20-day moving average (MA) of 0.96, above the 50-day MA of 1.03, and above the 200-day MA of 1.42, indicating a bearish trend. The MACD of -0.02 indicates Negative momentum. The RSI at 45.53 is Neutral, neither overbought nor oversold. The STOCH value of 66.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:3309.
C-MER Eye Care Holdings Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | HK$1.81B | 5.56 | 18.32% | 4.37% | -4.23% | 3.95% | |
75 Outperform | HK$1.81B | 8.38 | 7.71% | 9.29% | -3.21% | -6.77% | |
68 Neutral | HK$618.63M | 5.52 | 6.66% | 9.14% | -1.48% | 549.60% | |
65 Neutral | HK$793.04M | 14.57 | 4.33% | 1.99% | 11.23% | -31.73% | |
64 Neutral | HK$1.18B | 11.54 | 5.64% | 1.20% | 1.75% | ― | |
56 Neutral | HK$1.50B | 105.24 | 0.48% | 0.49% | -2.63% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
HK:3309
C-MER Eye Care Holdings Limited
0.96
-0.74
-43.40%
HK:1526
Rici Healthcare Holdings Ltd.
1.14
0.09
8.99%
HK:1846
EuroEyes International Eye Clinic Limited
2.48
-0.44
-14.95%
HK:2219
Chaoju Eye Care Holdings Ltd.
2.56
-0.15
-5.47%
HK:3689
Guangdong Kanghua Healthcare Co., Ltd. Class H
1.85
0.24
14.62%
HK:3886
Town Health International Medical Group Ltd.
0.22
-0.02
-7.14%
C-MER Eye Care Holdings Limited Corporate Events
C-MER Seeks Exclusive Hong Kong, Macau Rights to New Eye Drug in Strategic Series B Deal
Jun 30, 2026
C-MER Medical Holdings is pursuing a strategic investment that includes acquiring about 10.23% of a target company and securing exclusive rights to use the drug candidate ZVS101e in Hong Kong and Macau. The parties have passed resolutions to grant...
C-MER Medical Wins Shareholder Backing for Dividends and Capital Mandates at AGM
May 20, 2026
Shareholders of C-MER Medical Holdings Limited have approved all resolutions at the company’s annual general meeting held on 20 May 2026, with voting conducted by poll in accordance with Hong Kong listing rules. The meeting endorsed the audi...
C-MER Medical to Take 10.23% Stake in Target Firm via RMB112.6 Million Deal
May 20, 2026
C-MER Medical Holdings, via its subsidiary HK (International) Eye Care, has agreed to subscribe for new shares and acquire existing shares in a target medical company for a total consideration of RMB112.625 million. Upon completion, HK (Internatio...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.